GD2-specific chimeric antigen receptor-modified T cells targeting retinoblastoma – assessing tumor and T cell interaction

•This is the first report on targeted T cell therapy against retinoblastoma (RB).•A novel GD2-specific CAR T with safety switch effectively killed RB.•Repetitive antigen exposure, the tumor cells gradually lost GD2 expression and increased PD-L1 expression.•The first report on RB tumor evolvement after targeted T cell therapy.